Cargando…
Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adul...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509562/ https://www.ncbi.nlm.nih.gov/pubmed/36153530 http://dx.doi.org/10.1186/s13063-022-06732-9 |
_version_ | 1784797251782049792 |
---|---|
author | Endo, Akira Yamakawa, Kazuma Tagami, Takashi Umemura, Yutaka Takahashi, Kyosuke Nagasawa, Hiroki Araki, Yuichi Kojima, Mitsuaki Sera, Toshiki Yagi, Masayuki Yamamoto, Ryo Takahashi, Jiro Nakane, Masaki Takeda, Chikashi Narita, Chihiro Kazuma, Satoshi Okura, Hiroko Takahashi, Hiroyuki Wada, Takeshi Tahara, Shu Matsuoka, Ayaka Masaki, Todani Shiraishi, Atsushi Shimoyama, Keiichiro Yokokawa, Yuta Nakamura, Rintaro Sageshima, Hisako Yanagida, Yuichiro Takahashi, Kunihiko Otomo, Yasuhiro |
author_facet | Endo, Akira Yamakawa, Kazuma Tagami, Takashi Umemura, Yutaka Takahashi, Kyosuke Nagasawa, Hiroki Araki, Yuichi Kojima, Mitsuaki Sera, Toshiki Yagi, Masayuki Yamamoto, Ryo Takahashi, Jiro Nakane, Masaki Takeda, Chikashi Narita, Chihiro Kazuma, Satoshi Okura, Hiroko Takahashi, Hiroyuki Wada, Takeshi Tahara, Shu Matsuoka, Ayaka Masaki, Todani Shiraishi, Atsushi Shimoyama, Keiichiro Yokokawa, Yuta Nakamura, Rintaro Sageshima, Hisako Yanagida, Yuichiro Takahashi, Kunihiko Otomo, Yasuhiro |
author_sort | Endo, Akira |
collection | PubMed |
description | BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. METHODS: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. DISCUSSION: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. TRIAL REGISTRATION: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06732-9. |
format | Online Article Text |
id | pubmed-9509562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95095622022-09-26 Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial Endo, Akira Yamakawa, Kazuma Tagami, Takashi Umemura, Yutaka Takahashi, Kyosuke Nagasawa, Hiroki Araki, Yuichi Kojima, Mitsuaki Sera, Toshiki Yagi, Masayuki Yamamoto, Ryo Takahashi, Jiro Nakane, Masaki Takeda, Chikashi Narita, Chihiro Kazuma, Satoshi Okura, Hiroko Takahashi, Hiroyuki Wada, Takeshi Tahara, Shu Matsuoka, Ayaka Masaki, Todani Shiraishi, Atsushi Shimoyama, Keiichiro Yokokawa, Yuta Nakamura, Rintaro Sageshima, Hisako Yanagida, Yuichiro Takahashi, Kunihiko Otomo, Yasuhiro Trials Study Protocol BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. METHODS: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. DISCUSSION: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. TRIAL REGISTRATION: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06732-9. BioMed Central 2022-09-24 /pmc/articles/PMC9509562/ /pubmed/36153530 http://dx.doi.org/10.1186/s13063-022-06732-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Endo, Akira Yamakawa, Kazuma Tagami, Takashi Umemura, Yutaka Takahashi, Kyosuke Nagasawa, Hiroki Araki, Yuichi Kojima, Mitsuaki Sera, Toshiki Yagi, Masayuki Yamamoto, Ryo Takahashi, Jiro Nakane, Masaki Takeda, Chikashi Narita, Chihiro Kazuma, Satoshi Okura, Hiroko Takahashi, Hiroyuki Wada, Takeshi Tahara, Shu Matsuoka, Ayaka Masaki, Todani Shiraishi, Atsushi Shimoyama, Keiichiro Yokokawa, Yuta Nakamura, Rintaro Sageshima, Hisako Yanagida, Yuichiro Takahashi, Kunihiko Otomo, Yasuhiro Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title | Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title_full | Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title_fullStr | Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title_full_unstemmed | Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title_short | Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial |
title_sort | optimal target blood pressure in elderly with septic shock (optpress) trial: study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509562/ https://www.ncbi.nlm.nih.gov/pubmed/36153530 http://dx.doi.org/10.1186/s13063-022-06732-9 |
work_keys_str_mv | AT endoakira optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT yamakawakazuma optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT tagamitakashi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT umemurayutaka optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT takahashikyosuke optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT nagasawahiroki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT arakiyuichi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT kojimamitsuaki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT seratoshiki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT yagimasayuki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT yamamotoryo optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT takahashijiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT nakanemasaki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT takedachikashi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT naritachihiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT kazumasatoshi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT okurahiroko optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT takahashihiroyuki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT wadatakeshi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT taharashu optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT matsuokaayaka optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT masakitodani optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT shiraishiatsushi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT shimoyamakeiichiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT yokokawayuta optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT nakamurarintaro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT sageshimahisako optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT yanagidayuichiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT takahashikunihiko optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial AT otomoyasuhiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial |